Van Herk group (NASDAQ: PRQR) challenges ProQR 2026 AGM share capital proposals

Rhea-AI Filing Summary

Van Herk Investments B.V. and affiliated entities report beneficial ownership of 15,384,250 ProQR Therapeutics ordinary shares, representing 14.6% of the class based on 105,362,551 shares outstanding as of March 31, 2026.

The group amended its Schedule 13D to disclose that it will vote against agenda items 7, 8 and 9 at ProQR’s 2026 Annual General Meeting, which concern increasing authorized share capital, broad authority for the board to issue shares and authorization for share repurchases. Van Herk argues these proposals grant overly broad discretion over the capital structure, could cause substantial dilution without further shareholder approval, lack specific transaction justification and lack meaningful safeguards. They have engaged advisors to communicate with other shareholders and are evaluating potential legal proceedings while continuing to hold the shares for investment.

Insights

Corporate governance analyst

Large ProQR holder challenges broad capital-authorization proposals.

Van Herk Investments and related entities report beneficial ownership of 15,384,250 ordinary shares, or 14.6% of ProQR Therapeutics, based on 105,362,551 shares outstanding as of March 31, 2026. This updated Schedule 13D focuses on governance and capital-allocation powers rather than changing the stake size.

The group plans to vote against three 2026 AGM proposals that would increase authorized share capital, grant the board standing authority to issue shares up to the full authorization and authorize share repurchases. Their stated concerns center on potential substantial dilution without further shareholder approval, lack of specific financing needs and what they describe as insufficient limitations or safeguards.

They have hired a shareholder engagement advisor to discuss these issues with other investors and are evaluating possible legal proceedings relating to these capital-authorization matters. The filing states they acquired the shares for investment purposes and may consider a range of future actions, from additional purchases or sales to further engagement with the board and other shareholders. The ultimate impact will depend on AGM voting outcomes and any subsequent steps they choose to take.

Key Figures

Beneficial ownership: 15,384,250 shares Ownership percentage: 14.6% Shares outstanding: 105,362,551 shares +2 more

5 metrics

Beneficial ownership 15,384,250 shares Ordinary shares beneficially owned by reporting persons

Ownership percentage 14.6% Percent of ProQR ordinary shares represented by 15,384,250 shares

Shares outstanding 105,362,551 shares Ordinary shares outstanding as of March 31, 2026, per Form 6-K

Date of event June 2, 2026 Date of event requiring filing of this Schedule 13D/A amendment

Amendment number Amendment No. 5 Fifth amendment to original Schedule 13D on ProQR

Key Terms

beneficially owned, Sole Dispositive Power, authorized share capital, Annual General Meeting of Shareholders, +2 more

6 terms

beneficially owned financial

"with respect to Ordinary Shares, nominal value Euro 0.04 per share (the "Ordinary Shares"), beneficially owned by it"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Dispositive Power financial

"9 | Sole Dispositive Power 15,384,250.00 10 | Shared Dispositive Power 0.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

authorized share capital financial

"Agenda items 7, 8 and 9 relate to the proposed increase of the Issuer's authorized share capital"

The maximum number of shares a company is legally allowed to issue according to its governing documents. Think of it as the size of the blank checkbook a company keeps for selling ownership stakes: it sets an upper limit but does not mean all shares are in circulation. Investors care because a larger authorized amount makes it easier for the company to raise money or grant stock-based pay, which can dilute existing holdings and affect control and value per share.

Annual General Meeting of Shareholders financial

"Notice and Agenda for its 2026 Annual General Meeting of Shareholders (the "2026 AGM")"

Institutional Shareholder Services Inc. financial

"VHI understands that Institutional Shareholder Services Inc. ("ISS") has issued negative voting recommendations"

Schedule 13D regulatory

"The information previously provided in response to Item 5 is hereby amended and restated"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)

ProQR Therapeutics N.V.

(Name of Issuer)

Ordinary Shares, nominal value Euro 0.04 per share

(Title of Class of Securities)

N71542109

(CUSIP Number)

Van Herk Investments B.V.
Lichtenauerlaan 30,,
The Netherlands, P7, 3062 ME
31-10-241-1555

Evan S. Simpson
1 New Fetter Lane,,
London, X0, EC4A 1AN
44 20 795984-26

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/02/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): N71542109

1

Name of reporting person

Van Herk Investments B.V.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

BK, WC, PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 15,384,250.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 15,384,250.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

15,384,250.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.6 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

Row 13- Based on 105,362,551 ordinary shares, nominal value Euro 0.04 per share, of ProQR Therapeutics N.V. (the "Issuer") issued and outstanding as of March 31, 2026, as reported in the Issuer's Form 6-K filed with the SEC on May 12, 2026.

SCHEDULE 13D

CUSIP Number(s): N71542109

1

Name of reporting person

Van Herk Investments THI B.V.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

BK, WC, PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 15,384,250.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 15,384,250.00

11

Aggregate amount beneficially owned by each reporting person

15,384,250.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.6 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

Row 13- Based on 105,362,551 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of March 31, 2026, as reported in the Issuer's Form 6-K filed with the SEC on May 12, 2026.

SCHEDULE 13D

CUSIP Number(s): N71542109

1

Name of reporting person

Van Herk Private Equity Investments B.V.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

BK, WC, PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 15,384,250.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 15,384,250.00

11

Aggregate amount beneficially owned by each reporting person

15,384,250.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.6 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

Row 13- Based on 105,362,551 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of March 31, 2026, as reported in the Issuer's Form 6-K filed with the SEC on May 12, 2026.

SCHEDULE 13D

CUSIP Number(s): N71542109

1

Name of reporting person

Stichting Administratiekantoor Penulata

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

BK, WC, PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 15,384,250.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 15,384,250.00

11

Aggregate amount beneficially owned by each reporting person

15,384,250.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.6 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Row 13- Based on 105,362,551 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of March 31, 2026, as reported in the Issuer's Form 6-K filed with the SEC on May 12, 2026.

SCHEDULE 13D

CUSIP Number(s): N71542109

1

Name of reporting person

Van Herk Management Services B.V.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

BK, WC, PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 15,384,250.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 15,384,250.00

11

Aggregate amount beneficially owned by each reporting person

15,384,250.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.6 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

Row 13- Based on 105,362,551 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of March 31, 2026, as reported in the Issuer's Form 6-K filed with the SEC on May 12, 2026.

SCHEDULE 13D

CUSIP Number(s): N71542109

1

Name of reporting person

Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

BK, WC, PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 15,384,250.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 15,384,250.00

11

Aggregate amount beneficially owned by each reporting person

15,384,250.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.6 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

Row 13- Based on 105,362,551 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of March 31, 2026, as reported in the Issuer's Form 6-K filed with the SEC on May 12, 2026.

SCHEDULE 13D

CUSIP Number(s): N71542109

1

Name of reporting person

A. van Herk Holding B.V.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

BK, WC, PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 15,384,250.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 15,384,250.00

11

Aggregate amount beneficially owned by each reporting person

15,384,250.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.6 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

Row 13- Based on 105,362,551 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of March 31, 2026, as reported in the Issuer's Form 6-K filed with the SEC on May 12, 2026.

SCHEDULE 13D

CUSIP Number(s): N71542109

1

Name of reporting person

Stichting Administratiekantoor Abchrys

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

BK, WC, PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 15,384,250.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 15,384,250.00

11

Aggregate amount beneficially owned by each reporting person

15,384,250.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.6 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Row 13- Based on 105,362,551 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of March 31, 2026, as reported in the Issuer's Form 6-K filed with the SEC on May 12, 2026.

SCHEDULE 13D

CUSIP Number(s): N71542109

1

Name of reporting person

Adrianus van Herk

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

BK, WC, PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 15,384,250.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 15,384,250.00

11

Aggregate amount beneficially owned by each reporting person

15,384,250.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.6 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Row 13- Based on 105,362,551 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of March 31, 2026, as reported in the Issuer's Form 6-K filed with the SEC on May 12, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares, nominal value Euro 0.04 per share
(b)	Name of Issuer: ProQR Therapeutics N.V.
(c)	Address of Issuer's Principal Executive Offices: Zernikedreef 9, Leiden, NETHERLANDS , 2333 CK.
Item 1 Comment: This Schedule 13D/A (this "Amendment No. 5") amends the Schedule 13D filed on May 28, 2025, as Comment: amended by Amendment No. 1 filed on August 20, 2025, Amendment No. 2 filed on September 4, 2025, Amendment No. 3 filed on September 30, 2025 and Amendment No. 4 filed on February 6, 2026 (collectively, the "Original Schedule 13D," and as amended and supplemented by this Amendment No. 5, the "Schedule 13D"). Items 1, 2, 4, 5 and 7 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth in this Amendment No. 5. Except as amended hereby, the original disclosure set forth in the Original Schedule 13D shall remain unchanged. All capitalized terms used and not expressly defined herein have the respective meanings ascribed to such terms in the Original Schedule 13D.
Item 2.	Identity and Background
(a)	The information previously provided in response to Item 2 is hereby amended and restated by replacing the text thereof in its entirety with the following: This statement is being filed by (i) Van Herk Investments B.V., a private company with limited liability incorporated under the laws of the Netherlands ("VHI"), with respect to Ordinary Shares, nominal value Euro 0.04 per share (the "Ordinary Shares"), beneficially owned by it, (ii) Van Herk Investments THI B.V., a private company with limited liability incorporated under the laws of the Netherlands ("VHIT"), with respect to Ordinary Shares beneficially owned by VHI, (iii) Van Herk Private Equity Investments B.V., a private company with limited liability incorporated under the laws of the Netherlands ("VHPI"), with respect to Ordinary Shares beneficially owned by VHI and VHIT, (iv) Stichting Administratiekantoor Penulata, a foundation organized under the laws of the Netherlands ("Penulata"), with respect to Ordinary Shares beneficially owned by VHI, VHIT and VHPI, (v) Van Herk Management Services B.V., a private company with limited liability incorporated under the laws of the Netherlands ("VHMS"), with respect to Ordinary Shares beneficially owned by VHI, VHIT and VHPI, (vi) Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V., a private company with limited liability incorporated under the laws of the Netherlands ("OGBBA"), with respect to Ordinary Shares beneficially owned by VHI, VHIT, VHPI and VHMS, (vii) A. van Herk Holding B.V., a private company with limited liability incorporated under the laws of the Netherlands ("Holdings"), with respect to Ordinary Shares beneficially owned by VHI, VHIT, VHPI, VHMS and OGBBA, (viii) Stichting Administratiekantoor Abchrys, a foundation organized under the laws of the Netherlands ("Abchrys"), with respect to Ordinary Shares beneficially owned by VHI, VHIT, VHPI, VHMS, OGBBA and Holdings, and (ix) Adrianus van Herk ("Mr. van Herk") with respect to Ordinary Shares beneficially owned by VHI, VHIT, VHPI, VHMS, OGBBA, Holdings, Penulata and Abchrys. Each of Mr. van Herk, VHIT, VHPI, Penulata, VHMS, OGBBA, Holdings and Abchrys disclaims beneficial ownership of the securities covered by this statement.
(b)	The principal business address of each of Mr. van Herk, VHI, VHIT, VHPI, Penulata, VHMS, OGBBA, Holdings and Abchrys is: Lichtenauerlaan 30 3062 ME Rotterdam The Netherlands
(c)	Mr. van Herk is (i) an investor, (ii) the holder of all of the depositary receipts issued by Penulata and Abchrys, (iii) the sole board member of Penulata and Abchrys, and (iv) the sole managing director of VHMS, OGBBA and Holdings. Penulata holds substantially all of the issued and outstanding shares of VHPI. VHPI is the sole shareholder of VHIT. VHIT is the sole shareholder of VHI. VHI is principally engaged in making investments. Abchrys holds substantially all of the issued and outstanding shares of Holdings. Holdings is the sole shareholder of OGBBA. OGBBA is the sole shareholder of VHMS and is principally engaged in making investments. VHMS is the sole managing director of VHI, VHIT and VHPI.
(d)	During the last five years, none of the Reporting Persons, nor, to the knowledge of the Reporting Persons, none of the executive officers or directors of the Reporting Persons, if applicable, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	During the last five years, none of the Reporting Persons, nor, to the knowledge of the Reporting Persons, none of the executive officers or directors of the Reporting Persons, if applicable, has been a party to a civil proceeding of a judicial or administrative body of a competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	Each of VHI, VHIT, VHPI, VHMS, OGBBA and Holdings is a private company with limited liability incorporated under the laws of the Netherlands. Penulata and Abchrys are Netherlands foundations. Mr. van Herk is a citizen of the Netherlands.
Item 4.	Purpose of Transaction
	Item 4 of the Schedule 13D is amended by adding the following: On June 1, 2026, VHI sent written talking points (the "AGM Letter") to the Issuer's Chief Executive Officer stating that VHI will vote against agenda items 7, 8 and 9 set forth in the Issuer's Notice and Agenda for its 2026 Annual General Meeting of Shareholders (the "2026 AGM"), filed with the SEC on Form 6-K on May 4, 2026. Agenda items 7, 8 and 9 relate to the proposed increase of the Issuer's authorized share capital, the proposed standing authorization to the Issuer's board of directors (the "Board") to issue ordinary shares up to the full authorized share capital and the proposed authorization of the Board to acquire ordinary shares in the capital of the Issuer. In the AGM Letter, VHI set forth its reasons for voting against agenda items 7, 8 and 9, including: -the combined effect of agenda items 7, 8 and 9 would grant the Board overly broad discretion over the Issuer's capital structure; -the proposals could result in substantial dilution of existing shareholders without further shareholder approval or pre-emptive rights; -the Board has not identified a specific transaction, financing need or other demonstrated justification for the requested authorizations; -the proposed authorizations lack meaningful limitations, safeguards or conditions; and -the breadth of the requested authority is not appropriate in light of the Issuer's performance and existing governance concerns. A copy of the AGM Letter is filed as an exhibit herewith and is incorporated herein by reference. In addition, VHI understands that Institutional Shareholder Services Inc. ("ISS") has issued negative voting recommendations with respect to certain of the share-capital-related proposals to be considered at the 2026 AGM. VHI has engaged a shareholder engagement advisor to communicate with shareholders of the Issuer regarding the ISS recommendations and VHI's rationale for opposing agenda items 7, 8 and 9 at the 2026 AGM. The Reporting Persons have also retained counsel and are evaluating the initiation of legal proceedings against the Issuer, members of the Board and/or certain officers of the Issuer in order to protect the Reporting Persons' rights and interests and the interests of stockholders of the Issuer. Any such proceedings may seek declaratory, injunctive, equitable, monetary and/or other relief, and the Reporting Persons reserve all rights to pursue any and all available legal remedies. The Reporting Persons acquired the Ordinary Shares reported herein for investment purposes in the ordinary course of business. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Ordinary Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, engaging in communications with management and the board of directors of the Issuer, engaging in discussions with stockholders of the Issuer or other third parties about the Issuer and the Reporting Persons' investment, including potential business combinations or dispositions involving the Issuer or certain of its businesses, making recommendations or proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition), potential business combinations or dispositions involving the Issuer or certain of its businesses, or suggestions for improving the Issuer's financial and/or operational performance, evaluating the initiation of legal proceedings against the Issuer, members of the Board and/or certain officers of the Issuer, purchasing additional Ordinary Shares, selling some or all of their Ordinary Shares, engaging in short selling of or any hedging or similar transaction with respect to the Ordinary Shares, including swaps and other derivative instruments, or changing their intention with respect to any and all matters referred to in Item 4.
Item 5.	Interest in Securities of the Issuer
(a)	The information previously provided in response to Item 5 is hereby amended and restated by replacing the text thereof in its entirety with the following: The information set forth in or incorporated by reference in Items 2, 3, 4 and 6 and on the cover pages of this Schedule 13D is incorporated by reference in its entirety into this Item 5.
(b)	The information set forth in or incorporated by reference in Items 2, 3, 4 and 6 and on the cover pages of this Schedule 13D is incorporated by reference in its entirety into this Item 5.
(c)	Except as set forth in this Schedule 13D, no transactions in Ordinary Shares of the Issuer have been effected during the past sixty days by any of the Reporting Persons.
(d)	Except as set forth herein, to the knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any securities of the Issuer beneficially owned by the Reporting Persons as described in this Item 5.
(e)	Not applicable.
Item 7.	Material to be Filed as Exhibits.
	Item 7 of the Schedule 13D is amended by adding the following: 99.1* Talking points, delivered to the Chief Executive Officer of the Issuer on June 2, 2026, from Van Herk Investments B.V. * Filed herewith.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Van Herk Investments B.V.

Signature:	/s/ Erik G.A. Esveld
Name/Title:	Erik G.A. Esveld/Attorney-In-Fact*
Date:	06/03/2026

Van Herk Investments THI B.V.

Signature:	/s/ Erik G.A. Esveld
Name/Title:	Erik G.A. Esveld/Attorney-In-Fact*
Date:	06/03/2026

Van Herk Private Equity Investments B.V.

Signature:	/s/ Erik G.A. Esveld
Name/Title:	Erik G.A. Esveld/Attorney-In-Fact*
Date:	06/03/2026

Stichting Administratiekantoor Penulata

Signature:	/s/ Erik G.A. Esveld
Name/Title:	Erik G.A. Esveld/Attorney-In-Fact*
Date:	06/03/2026

Van Herk Management Services B.V.

Signature:	/s/ Erik G.A. Esveld
Name/Title:	Erik G.A. Esveld/Attorney-In-Fact*
Date:	06/03/2026

Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V.

Signature:	/s/ Erik G.A. Esveld
Name/Title:	Erik G.A. Esveld/Attorney-In-Fact*
Date:	06/03/2026

A. van Herk Holding B.V.

Signature:	/s/ Erik G.A. Esveld
Name/Title:	Erik G.A. Esveld/Attorney-In-Fact*
Date:	06/03/2026

Stichting Administratiekantoor Abchrys

Signature:	/s/ Erik G.A. Esveld
Name/Title:	Erik G.A. Esveld/Attorney-In-Fact*
Date:	06/03/2026

Adrianus van Herk

Signature:	/s/ Erik G.A. Esveld
Name/Title:	Erik G.A. Esveld/Attorney-In-Fact*
Date:	06/03/2026

Comments accompanying signature:

* Pursuant to a Power of Attorney, dated as of September 16, 2019, by and among the Reporting Persons.

FAQ

How much of ProQR Therapeutics (PRQR) does Van Herk currently own?

Van Herk and affiliated entities report beneficial ownership of 15,384,250 ProQR ordinary shares, representing 14.6% of the class. The percentage is calculated using 105,362,551 ordinary shares outstanding as of March 31, 2026, as disclosed in ProQR’s Form 6-K filed on May 12, 2026.

What is the main purpose of Van Herk’s latest Schedule 13D/A on ProQR (PRQR)?

The amendment updates Van Herk’s beneficial ownership and discloses opposition to specific 2026 AGM share-capital proposals. It explains why they will vote against agenda items 7, 8 and 9, and describes their engagement with other shareholders and consideration of possible legal proceedings regarding these matters.

Which ProQR (PRQR) AGM agenda items is Van Herk opposing and why?

Van Herk intends to vote against agenda items 7, 8 and 9 at ProQR’s 2026 AGM. These relate to increasing authorized share capital, broad authority for the board to issue shares and authorization for share repurchases. Van Herk cites concerns over overly broad discretion, potential substantial dilution and a lack of clear justification or safeguards.

What governance concerns does Van Herk raise about ProQR (PRQR) in this filing?

Van Herk argues the proposed capital authorizations give the board overly broad discretion over ProQR’s capital structure. They highlight risks of substantial dilution without further shareholder approval, absence of a specific financing need, limited safeguards and the breadth of the requested authority relative to ProQR’s performance and existing governance concerns.

Is Van Herk considering legal action related to its ProQR (PRQR) investment?

The filing states that the reporting persons are evaluating the initiation of legal proceedings involving ProQR, its board members and/or certain officers. Any such actions could seek declaratory, injunctive, equitable, monetary or other relief, with all legal remedies expressly reserved by the reporting persons.

How is Van Herk engaging other ProQR (PRQR) shareholders ahead of the 2026 AGM?

Van Herk has engaged a shareholder engagement advisor to communicate with other ProQR shareholders. The advisor discusses proxy firm ISS’s negative recommendations on certain share-capital-related proposals and Van Herk’s rationale for opposing agenda items 7, 8 and 9 at the 2026 Annual General Meeting of Shareholders.